Intravitreal (IVT) Injectable Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)
The global Intravitreal (IVT) Injectable Market is poised for remarkable growth, with a projected value of $26.52 billion by 2031, according to a comprehensive market analysis. This surge in market value is primarily attributed to the increasing incidence of retinal diseases, the development of novel drugs, and the rising demand for Intravitreal (IVT) injectables due to their effectiveness and safety profile.
Intravitreal Injection: A Game-Changer in Retinal Disease Management
Retinal diseases, such as diabetic retinopathy, macular degeneration, endophthalmitis, and retinal vein occlusion, have been significant causes of visual impairment and blindness worldwide. Intravitreal injection has emerged as a secure and effective therapeutic option for these conditions, offering hope to countless individuals suffering from retinal problems.
Key Market Drivers
• Increasing Incidence of Retinal Diseases: The prevalence of vitreo-retinal diseases has made Intravitreal (IVT) injectables an essential part of retinal disease therapy. Patients with chronic retinal conditions often require recurring intravitreal injections, fueling substantial market growth.
• Development of Novel Drugs: Pharmaceutical companies are actively researching and developing novel medications to address unmet needs in the treatment of intraocular disorders. These innovations are expected to be delivered via Intravitreal (IVT) injectables, further driving market expansion.
• Increased Demand for Intravitreal (IVT) Injectables: Recognized for their superior efficacy and safety compared to alternative treatments, Intravitreal (IVT) injectables are gaining popularity among healthcare professionals. They are versatile, offering treatment for a wide range of retinal disorders, including anticancer, antivascular endothelial growth factor, anti-inflammatory, antibacterial, surgical gases, and other medicinal substances.
• Increasing Adoption of Anti-VEGF Therapies: Chronic retinal diseases like diabetic retinopathy, macular degeneration, and retinal vein occlusion are often treated with anti-VEGF therapies. The rising prevalence of these conditions has led to a surge in the adoption of anti-VEGF therapies, contributing significantly to the demand for Intravitreal (IVT) injectables.
Challenges Ahead
However, the market faces challenges associated with Intravitreal (IVT) injectables, including the risks and complications linked to repeated injections, such as eye infection, inflammation, retinal detachment, and vitreous hemorrhage.
Impact of Covid-19 Pandemic
The Covid-19 pandemic temporarily affected the Intravitreal (IVT) Injectable Market, causing a reduction in clinic visits and injectable treatments due to lockdowns and healthcare system pressures. Nonetheless, as restrictions eased in September 2021, demand for Intravitreal (IVT) injectables rebounded.
Competitive Analysis
The Intravitreal (IVT) Injectable Market is highly competitive, featuring global industry giants. Prominent players are expanding their product portfolios through organic and inorganic methods, including product launches, collaborations, and agreements.
Key Companies Profiled
• Regeneron Pharmaceuticals, Inc.
• Bausch & Lomb
• Novartis AG
• Allergan
• Alimera Sciences
• ThromboGenics, Inc.
• Bristol-Myers Squibb Company
• Other industry leaders
Key Segments of Intravitreal Injectable Industry Research:
By Indication
• Macular Degeneration
• Diabetic Retinopathy
• Retinal Vein Occlusion
• Endophthalmitis
• Others
By Drug Class
• Anti-VEGF
• Corticosteroids
• Antibiotics
• Antivirals
• Antifungals
By Region
• North America
• Latin America
• Europe
• Asia Pacific
• Middle East & Africa (MEA)
Please note: The PDF e-mail from publisher version of this report is for a global site license. Delivery Timelines - 5 working days.